Matrix metalloproteinases in cardiovascular disease

Liu, Peter; Sun, Mei; Sader, Sawsan

doi:10.1016/s0828-282x(06)70983-7

Cited by 161 publications

(128 citation statements)

References 25 publications

(34 reference statements)

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…Once they are secreted in the extracellular space, MMPs may be activated by several proteases, other MMPs, and ROS, in particular peroxynitrite [1,15,16]. Some authors have described an overexpression of MMP-9 in older atherosclerotic lesions [20], responsible for a large remodeling characterized by fibrosis, matrix degradation and angiogenesis, resulting in plaque instability and rupture [11,20]. However, MMP-2 seems to be associated with a more stable plaque phenotype and rare haemorrhages [11].…”

Section: Introductionmentioning

confidence: 99%

Gelatinases and their tissue inhibitors in a group of subjects with obstructive sleep apnea syndrome

Hopps¹,

Canino²,

Montana

et al. 2016

View full text Add to dashboard Cite

Abstract. Obstructive sleep apnea syndrome (OSAS) is associated with an elevated risk of cardiovascular events and stroke. Matrix metalloproteinases (MMPs) are endopeptidases involved in extracellular matrix degradation and then in the development and progression of cardiovascular diseases. Our aim was to evaluate plasma levels of gelatinases (MMP-2 and MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in a group of subjects with OSAS. We enrolled 48 subjects (36 men and 12 women; mean age 49.7 ± 14.68 yrs) with OSAS diagnosed with a 1-night cardiorespiratory study and then we subdivided these subjects into two subgroups according to the apnea/hypopnea index (AHI): Low (L = 21 subjects with AHI <30) and High (H = 27 subjects with AHI >30). We measured plasma concentration of the gelatinases and their inhibitors using ELISA kits. We observed a significant increase in plasma concentration of MMP-9, MMP-2, TIMP-1 and TIMP-2 in the entire group of OSAS subjects and in the two subgroups, with higher levels in the H in comparison with the L subgroup. In the whole group of OSAS subjects we also noted a significant decrease in MMP-9/TIMP-1 ratio in comparison with normal controls. Only MMP-9 was significantly correlated with the severity of the disease, expressed as AHI, with the oxygen desaturation index and also with the mean oxygen saturation. MMPs pattern is altered in OSAS and significantly influenced by the severity of the disease; it probably contributes to the vascular remodeling that leads to the atherosclerotic disease and cardiovascular complications.

show abstract

Section: Introductionmentioning

confidence: 99%

Gelatinases and their tissue inhibitors in a group of subjects with obstructive sleep apnea syndrome

Hopps¹,

Canino²,

Montana

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Following MI, the ECM is degraded and synthesized through a process that is modulated by the balance between matrix metalloproteinase (MMP) activity and the function of the main source of most of the ECM, the fibroblast [6]. Presently, 23 human MMPs have been identified, and although they share a common homology, their functions vary tremendously [2].…”

Section: Introductionmentioning

confidence: 99%

Matrix Metalloproteinases: Drug Targets for Myocardial Infarction

Yabluchanskiy¹,

Li²,

Chilton³

et al. 2013

CDT

View full text Add to dashboard Cite

Myocardial infarction (MI) remains a major cause of morbidity and mortality worldwide. Rapid advances in the treatment of acute MI have significantly improved short-term outcomes in patient, due in large part to successes in preventing myocardial cell death and limiting infarct area during the time of ischemia and subsequent reperfusion. Matrix metalloproteases (MMPs) play key roles in post-MI cardiac remodeling and in the development of adverse outcomes. This review highlights the importance of MMPs in the injury and remodeling response of the left ventricle and also discusses their potential as therapeutic targets Additional pre-clinical and clinical research is needed to further investigate and understand the cardioprotective effects of MMPs inhibitors.

show abstract

“…After ischemic injury, there seems there to be local formation of inflammatory cytokines, such as tumor necrosis factor (TNF), platelet-derived growth factor, and vascular endothelial growth factor [197]. A significant component of regulation of MMP production following myocardial infarction is induced by the local inflammatory cytokines, which is practically what is observed in HF.…”

Section: Heart Biomarkers Of Oxidative Stressmentioning

confidence: 99%

Free Radicals and Biomarkers Related to the Diagnosis of Cardiorenal Syndrome

Restini¹,

Pereira²,

Geleilete³

2016

Free Radicals and Diseases

View full text Add to dashboard Cite

The National Heart, Lung, and Blood Institute Working Group has postulated the cardiorenal syndrome (CRS) as an interaction between the kidneys and the cardiovascular system in which therapy to relieve congestive heart failure (HF) symptoms is limited by the further worsening renal function. CRS is classified from type I to V, taking into account the progression of the symptoms in terms of mechanisms, clinical conditions, and biomarkers. Experimental and clinical studies have shown the kidney as both a trigger and a target to sympathetic nervous system (SNS) overactivity. Renal damage and ischemia, activation of the renin angiotensin aldosterone system (RAAS), and dysfunction of nitric oxide (NO) system are associated with kidney adrenergic activation. Indeed, the imbalances of RAAS and/or SNS share an important common process in CRS: the activation and production of free radicals, especially reactive oxygen species (ROS). The present chapter addresses connections of the free radicals as potential biomarkers as the imbalances in the RAAS and the SNS are developed. Understanding the involvement of free radicals in CRS may bring knowledge to design studies in order to develop accurate pharmacological interventions.

show abstract

Matrix metalloproteinases in cardiovascular disease

Cited by 161 publications

References 25 publications

Gelatinases and their tissue inhibitors in a group of subjects with obstructive sleep apnea syndrome

Gelatinases and their tissue inhibitors in a group of subjects with obstructive sleep apnea syndrome

Matrix Metalloproteinases: Drug Targets for Myocardial Infarction

Free Radicals and Biomarkers Related to the Diagnosis of Cardiorenal Syndrome

Contact Info

Product

Resources

About